Q2 2026 BioCardia Inc Earnings Call Transcript
Key Points
- Positive regulatory outcomes in Japan and the US support the approvability of BioCardia's cardiac cell therapy and Helix delivery catheter.
- PMDA's consultation record supports advancing to a Shonin pre-market submission for CardiAMP cell therapy in Japan, with a potential initial market of 20,000 patients.
- FDA confirmed that the ongoing CardiAMP Heart Failure 2 trial may support premarket approval, viewing it as a confirmatory trial.
- FDA agreed on two pathways for Helix marketing clearance, including a de novo pathway, with no concerns on safety or device performance.
- BioCardia has a strong cash position with $5.4 million in cash, providing runway into 2027, and raised $4.9 million via an ATM facility at a low cost of capital.
- PMDA requested additional data on guideline-directed medical therapy compliance and revascularization eligibility, requiring extra documentation and audits.
- The FDA has not yet provided formal meeting minutes for the Helix de novo pre-submission, causing delays in clarity for the approval pathway.
- Enrollment in the CardiAMP Heart Failure 2 trial is slow, with only four active sites and no disclosed patient numbers, potentially delaying the confirmatory study.
- The company faces uncertainty regarding the primary outcome measure, particularly the third tier of the composite endpoint, which has faced scientific criticism.
- BioCardia's cash runway is limited, and the company may need additional financing to accelerate the CardiAMP Heart Failure 2 program, despite current capital sufficiency for the PMDA submission.
Good day everyone and welcome to the Biocardia Q2 2026 financial results and corporate upate conference call.
All participants will be in a listen-only mode. (Operator instructions)
Participants of this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately one hour after the end of today's conference.
I would now like to turn the floor over to Miranda Pato of Biocardia Investor Relations. Please go ahead, Miranda.
Good afternoon, and thank you for participating in today's conference call. Joining me from Biocardia's leadership team are Peter Altman, President and Chief Executive Officer, and David McClung, the company's Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address Biocardia's expectations for future performance and operational
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
